Skip to content

EBITDA at other companies

Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
-$48.01M-204%
Veracyte logo
VeracyteVCYT
$28.08M+240%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$90.3M-49.2%
Guardant Health logo
Guardant HealthGH
Natera, Inc. logo
Natera, Inc.NTRA
Danaher logo
DanaherDHR

Other financials

Income statement

See full
Revenue$70.9M+35.1%
Gross profit$52.2M+47.1%
Operating income-$19.2M+35.1%
Net income-$20.0M+32.9%
EPS (diluted)-$0.13+35.0%

Balance sheet

See full
Cash & equivalents$77.6M+53.2%
Total debt$208.2M-5.6%
Total equity$216.3M+13.6%
Total assets$505.9M-1.0%

Cash flow

See full
Operating cash flow-$9.5M+66.5%
CapEx$796.0K-36.8%
Free cash flow-$10.3M+65.3%

Valuation

See full
Market cap$2.76B+93.6%
Enterprise value$2.89B+78.0%
P/S9.3×+1.8×

Profitability

See full
Gross margin75.3%+12.7pp
Operating margin-15.8%-7.0pp
Net margin-16.8%-7.3pp
FCF margin-10.5%-4.6pp

Returns & leverage

See full
Return on equity-24.4%-9.2pp
Debt / equity-0.2×
Current ratio3.4×+0.4×

Where this comes from

Calculated from Adaptive Biotechnologies’s reported figures.

$19.2Mebit+
$3.8MDepreciation Depletion & Amortization
=-$15.37M

The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Adaptive Biotechnologies's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Adaptive Biotechnologies's EBITDA?
Adaptive Biotechnologies (ADPT) reported EBITDA of -$15.37M in Q1 2026.
How has Adaptive Biotechnologies's EBITDA changed year-over-year?
Adaptive Biotechnologies's EBITDA increased by 38.2% year-over-year, from -$24.87M to -$15.37M.
What is the long-term trend for Adaptive Biotechnologies's EBITDA?
Over 4 years (2021 to 2025), Adaptive Biotechnologies's EBITDA has grown at a -33.0% compound annual growth rate (CAGR), from -$195.01M to -$39.29M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.